PL3958976T3 - Związki zawierające n-metylo-2-pirydon i sole dopuszczalne farmaceutycznie - Google Patents

Związki zawierające n-metylo-2-pirydon i sole dopuszczalne farmaceutycznie

Info

Publication number
PL3958976T3
PL3958976T3 PL20721195.4T PL20721195T PL3958976T3 PL 3958976 T3 PL3958976 T3 PL 3958976T3 PL 20721195 T PL20721195 T PL 20721195T PL 3958976 T3 PL3958976 T3 PL 3958976T3
Authority
PL
Poland
Prior art keywords
pyridone
methyl
compounds
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
PL20721195.4T
Other languages
English (en)
Inventor
Christopher Andrew WOODLAND
Mark Bell
Original Assignee
Tay Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tay Therapeutics Limited filed Critical Tay Therapeutics Limited
Publication of PL3958976T3 publication Critical patent/PL3958976T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL20721195.4T 2019-04-24 2020-04-22 Związki zawierające n-metylo-2-pirydon i sole dopuszczalne farmaceutycznie PL3958976T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1905721.5A GB201905721D0 (en) 2019-04-24 2019-04-24 Compounds
PCT/EP2020/061173 WO2020216779A1 (en) 2019-04-24 2020-04-22 Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
PL3958976T3 true PL3958976T3 (pl) 2025-10-06

Family

ID=66810205

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20721195.4T PL3958976T3 (pl) 2019-04-24 2020-04-22 Związki zawierające n-metylo-2-pirydon i sole dopuszczalne farmaceutycznie

Country Status (19)

Country Link
US (1) US12384777B2 (pl)
EP (2) EP4616856A3 (pl)
JP (2) JP7671503B2 (pl)
KR (1) KR20220012250A (pl)
CN (2) CN113924298A (pl)
AU (1) AU2020263112A1 (pl)
BR (1) BR112021021284A2 (pl)
CA (1) CA3148317A1 (pl)
DK (1) DK3958976T3 (pl)
EA (1) EA202192905A1 (pl)
ES (1) ES3040060T3 (pl)
FI (1) FI3958976T3 (pl)
GB (2) GB201905721D0 (pl)
IL (1) IL287470B2 (pl)
MX (1) MX2021013014A (pl)
PL (1) PL3958976T3 (pl)
PT (1) PT3958976T (pl)
WO (1) WO2020216779A1 (pl)
ZA (1) ZA202109179B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
WO2022012456A1 (en) * 2020-07-17 2022-01-20 Chengdu Easton Biopharmaceuticals Co., Ltd. Novel heterocyclic compounds as bet inhibitors
GB202016977D0 (en) * 2020-10-26 2020-12-09 In4Derm Ltd Compounds
CN113582859A (zh) * 2021-06-28 2021-11-02 佳尔科生物科技南通有限公司 一种4-酚氧基-3-氨基苯甲醚的制备方法
MX2024000238A (es) 2021-06-29 2024-01-30 Tay Therapeutics Ltd Derivados de pirrolopiridona utiles en el tratamiento del cancer.
CN115611890B (zh) * 2021-07-15 2024-05-31 成都硕德药业有限公司 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途
US20250339409A1 (en) * 2021-11-03 2025-11-06 Vyne Therapeutics Inc. Uses of pan bet inhibitors
CN115819412B (zh) * 2022-05-30 2025-03-14 成都苑东生物制药股份有限公司 一种n-杂环bet溴结构域抑制剂的合成方法及其中间体
WO2024220589A2 (en) * 2023-04-18 2024-10-24 Vyne Therapeutics Inc. Uses of pan bet inhibitors cross-reference to related applications

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193011A (en) 1979-03-19 1983-03-15 Ici Australia Ltd Diarylamine derivatives intermediates herbicidal compositions
GB2165537B (en) 1984-09-05 1987-07-29 Wyeth John & Brother Ltd N-aryl-pyridine-4-carboxamides and their n-oxides
US4748183A (en) 1986-06-13 1988-05-31 Warner-Lambert Company N-1H-tetrazol-5-yl-2-thiophene carboxamides, N-1H-tetrazol-5-yl-2-pyrrole carboxamides, N-1H-tetrazol-5-yl-2-furan carboxamides, and anti-allergic and anti-inflammatory use thereof
AT387966B (de) 1987-10-08 1989-04-10 Warner Lambert Co Neue n-1h-tetrazol-5-yl-(5-ring)-carboxamidderivate sowie verwendung derartiger verbindungen
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
US4874794A (en) 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
EP0511366A1 (en) 1990-11-21 1992-11-04 Beckman Instruments, Inc. Chemiluminescent compounds
US5880066A (en) 1990-12-11 1999-03-09 Monsanto Company Safened herbicidal sulfonamide compositions
FR2673628B1 (fr) 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
CZ290470B6 (cs) 1991-10-18 2002-07-17 Monsanto Technology Llc 5 či 6 členné aromáty jako fungicidy pro kontrolu stéblolamu rostlin, způsob kontroly a fungicidní směs k provedení tohoto způsobu
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
EP0603419A4 (en) 1992-07-13 1994-10-12 Japan Tobacco Inc NEW THIAZOLIDINEDIONE COMPOUND AND ITS USE.
MX9308025A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
GB9303825D0 (en) 1993-02-25 1993-04-14 Smithkline Beecham Plc Novel compounds
IT1263089B (it) 1993-04-26 1996-07-24 Menarini Farma Ind Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
DE4412334A1 (de) 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0766676B1 (en) 1994-06-24 2002-05-22 Euroceltique S.A. Compounds for inhibiting phosphodiesterase iv
EP0807112B1 (en) 1995-02-03 2001-09-05 PHARMACIA & UPJOHN COMPANY Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials
CZ64598A3 (cs) 1995-09-18 1998-08-12 Basf Aktiengesellschaft Derivát fenyloctové kyseliny, způsob jeho přípravy, meziprodukt pro tuto přípravu a prostředek, který ho obsahuje
WO1998015278A1 (en) 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
AP9901643A0 (en) 1997-04-28 1999-10-02 Texas Biotechnology Corp Sulfonamides for treatment of endothelin-mediated disorders.
EP1000932B9 (en) 1997-06-27 2005-12-28 Fujisawa Pharmaceutical Co., Ltd. Aromatic ring derivatives
GEP20033001B (en) 1998-08-27 2003-06-25 Pfizer Prod Inc Alkynyl-Substituted Quinolin-2-One Derivatives Useful As Anticancer Agents
JP3494409B2 (ja) 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗がん剤として有用なアルキニル置換キノリン−２−オン誘導体
JP2000109467A (ja) 1998-10-05 2000-04-18 Sumitomo Pharmaceut Co Ltd イミダゾール誘導体を含有する医薬
US6413997B1 (en) 1998-10-23 2002-07-02 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted heterocyclyl)-1,2,4-triazole compounds
WO2000033836A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation 5-membered heterocycles for the treatment of human diseases involving modulators of selectins
AUPP921299A0 (en) 1999-03-15 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
EP1068866A3 (de) 1999-07-12 2004-03-17 Ciba SC Holding AG Verwendung von Mischungen aus Mikropigmenten zur Bräunungsverhinderung und Aufhellung der Haut und Haare
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
WO2001053257A2 (en) 2000-01-19 2001-07-26 Cadila Healthcare Ltd. Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
EP1276726A2 (en) 2000-04-27 2003-01-22 Abbott Laboratories Substituted phenyl farnesyltransferase inhibitors
US20020019527A1 (en) 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
US20020151563A1 (en) 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
MXPA04005999A (es) 2001-12-21 2005-07-13 Taisho Pharma Co Ltd Derivado de piperazina.
US20070142449A1 (en) 2002-03-29 2007-06-21 Yung Shin Pharmaceutical Ind. Co., Ltd. Angiogenesis inhibitors
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
AR043850A1 (es) 2003-04-17 2005-08-17 Bayer Pharmaceuticals Corp Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos
JP2005035983A (ja) 2003-06-25 2005-02-10 Taisho Pharmaceut Co Ltd 不安神経症又はうつ症治療薬
US7317032B2 (en) 2003-09-02 2008-01-08 Bristol-Myers Squibb Co. Imidazolyl inhibitors of 15-lipoxygenase
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
CA2594488C (en) 2005-01-10 2015-04-28 University Of Connecticut Novel heteropyrrole analogs acting on cannabinoid receptors
WO2006103254A1 (en) 2005-04-01 2006-10-05 Clariant International Ltd Betaines of squaric acid for use in optical layers for optical data recording
DE102005031580A1 (de) 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
FR2889190A1 (fr) 2005-08-01 2007-02-02 Merck Sante Soc Par Actions Si Nouveaux derives d'imidazoles carboxamides comme inhibiteurs de fructose -1,6-biphosphatase et compositions pharmaceutiques les contenant
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
US8093251B2 (en) 2006-06-07 2012-01-10 Nissan Chemical Industries, Ltd. Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
TWI387585B (zh) 2006-09-01 2013-03-01 Dow Agrosciences Llc 殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺
EP2104671A2 (en) 2006-09-25 2009-09-30 Mutabilis SA Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
US20100113421A1 (en) 2006-10-06 2010-05-06 Williams Theresa M Non-nucleoside reverse transcriptase inhibitors
DK2081937T3 (da) 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Triazolopyridazin-proteinkinasemodulatorer
WO2008064318A2 (en) 2006-11-22 2008-05-29 University Of Medicine And Dentistry Of New Jersey Peripheral opioid receptor active compounds
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
US7511149B2 (en) 2007-02-09 2009-03-31 Dow Agrosciences Llc Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
BRPI0721218A2 (pt) 2007-02-09 2013-01-01 Dow Agrosciences Llc processo para a oxidação de determinadas sulfiliminas substituìdas para sulfoximinas inseticidas
KR101437710B1 (ko) 2007-02-26 2014-09-03 다우 아그로사이언시즈 엘엘씨 특정 치환된 술필이민의 제조 방법
WO2008120759A1 (ja) 2007-03-30 2008-10-09 Japan Tobacco Inc. ウレア化合物およびその用途
JP2010526793A (ja) 2007-05-10 2010-08-05 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのピラゾール誘導体
AU2008258508A1 (en) 2007-06-08 2008-12-11 Bayer Cropscience Ag Fungicide heterocyclyl-pyrimidinyl-amino derivatives
JP5450083B2 (ja) 2007-11-01 2014-03-26 武田薬品工業株式会社 複素環化合物
WO2009067233A1 (en) 2007-11-20 2009-05-28 Millennium Pharmaceuticals, Inc. Beta carbolines and uses thereof
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
EP2070916A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMORAL MEDIUM
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
CA2727078A1 (en) 2008-06-23 2009-12-30 Basf Se Sulfoximinamide compounds for combating animal pests
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
SI3135672T1 (sl) 2008-10-10 2020-07-31 Vm Discovery, Inc. Sestavki in postopki za zdravljenje motenj, bolečin in drugih bolezni povezanih z uporabo alkohola
JP2012506386A (ja) 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
US20100240720A1 (en) 2009-03-20 2010-09-23 Burnham Institute For Medical Research Allosteric jnk inhibitors
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
ES2654423T3 (es) 2009-11-05 2018-02-13 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiacepina
RS53179B (sr) 2009-11-05 2014-06-30 Glaxosmithkline Llc Benzodiazepinski inhibitor bromodomena
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
EP2423208A1 (en) 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
GB201018147D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
GB201018154D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
GB201018149D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Method of treatment
GB201020015D0 (en) 2010-11-25 2011-01-12 Glaxo Group Ltd Method of treatment
WO2012085081A1 (en) 2010-12-22 2012-06-28 Basf Se Sulfoximinamide compounds for combating invertebrate pests ii
CN102174035B (zh) 2011-03-11 2015-01-07 中国药科大学 芳香双酰肼类plk1抑制剂及其用途
CN102304108B (zh) 2011-06-28 2013-11-06 中国药科大学 五元杂环双羰基衍生物及其抗多药耐药细菌上的用途
PL2736887T3 (pl) 2011-07-29 2018-03-30 Karyopharm Therapeutics, Inc. Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania
JP2013041225A (ja) 2011-08-19 2013-02-28 Fujifilm Corp 感光性樹脂組成物、並びにこれを用いた感光性フイルム、感光性積層体、永久パターン形成方法およびプリント基板
JP2013041226A (ja) 2011-08-19 2013-02-28 Fujifilm Corp 感光性樹脂組成物、並びにこれを用いた感光性フイルム、感光性積層体、永久パターン形成方法およびプリント基板
US9650395B2 (en) 2011-08-29 2017-05-16 Ptc Therapeutics, Inc. Antibacterial compounds and methods for use
CN102977090B (zh) 2011-09-06 2016-04-06 北京大学 四氢叶酸类似物的合成方法
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
GB201120993D0 (en) 2011-12-06 2012-01-18 Imp Innovations Ltd Novel compounds and their use in therapy
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
PL2814812T3 (pl) 2012-02-16 2017-10-31 Dow Agrosciences Llc Sposób wytwarzania związków sulfiliminowych
JP6217629B2 (ja) 2012-05-31 2017-10-25 住友化学株式会社 縮合複素環化合物
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
WO2014004863A2 (en) 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
US10112911B2 (en) 2012-06-28 2018-10-30 Abbvie Inc. Substituted cyanoguanidines as oral anti-virals
PT2873658T (pt) 2012-07-12 2018-12-05 Nissan Chemical Corp Composto de amida substituída com oxima e agente de controlo de pragas
BR112015002152B1 (pt) 2012-08-02 2021-04-27 Nerviano Medical Sciences S.R.L. Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos
GB201215942D0 (en) 2012-09-06 2012-10-24 Glaxo Group Ltd Method of treatent
HK1213889A1 (zh) 2012-11-21 2016-07-15 安吉奥斯医药品有限公司 殼氨醯胺酶抑制劑及使用方法
AR094112A1 (es) 2012-12-20 2015-07-08 Novartis Tiergesundheit Ag (hetero)arilacrilamidas utiles para controlar ectoparasitos
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
WO2014125408A2 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
CN108440528A (zh) 2013-03-12 2018-08-24 艾伯维公司 四环布罗莫结构域抑制剂
US9493411B2 (en) 2013-03-12 2016-11-15 Abbvie Inc. Pyrrole-3-carboxamide bromodomain inhibitors
NZ710765A (en) 2013-03-14 2020-05-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
US20160031839A1 (en) 2013-03-14 2016-02-04 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
BR112015023184A2 (pt) 2013-03-15 2017-11-21 Constellation Pharmaceuticals Inc método para o tratamento de uma doença, inibidor e seu uso, composição, método de identificação de um composto e método para inibir a produção de il-4, il-5 e il-13
EP2792355A1 (en) 2013-04-17 2014-10-22 Albert-Ludwigs-Universität Freiburg Compounds for use as bromodomain inhibitors
WO2014170350A1 (en) 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
GB201309932D0 (en) 2013-06-04 2013-07-17 Univ Leicester Novel pyrrole derivative
GB201310126D0 (en) 2013-06-06 2013-07-24 Univ Leicester Novel pyrrole derivatives
RU2016102647A (ru) 2013-06-28 2017-08-01 Эббви Инк. Ингибиторы бромодомена
JP6545177B2 (ja) 2013-09-29 2019-07-17 セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド 抗菌薬としてのアリール置換アミノメチルスペクチノマイシン類似体
KR20160060765A (ko) 2013-10-11 2016-05-30 제넨테크, 인크. 암 면역요법을 위한 cbp/ep300 브로모도메인 억제제의 용도
GB201319277D0 (en) 2013-10-31 2013-12-18 Akthelia Pharmaceuticals A new class of inducers of antimicrobial compounds
US20150148372A1 (en) * 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081280A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015089075A1 (en) 2013-12-09 2015-06-18 Abbvie Inc. Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors
US10064798B1 (en) 2013-12-13 2018-09-04 The University Of Toledo Method for modulating pigmentation by targeting BET bromodomain proteins
US20170007595A1 (en) 2014-01-24 2017-01-12 The Brigham And Women's Hospital, Inc. Nsd3 inhibitors for treatment of cancers
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US20170027955A1 (en) 2014-04-04 2017-02-02 Constellation Pharmaceuticals, Inc. Expression levels of bcl-xl, bcl2, bcl-w, and bad and cancer therapies
UA119870C2 (uk) 2014-04-23 2019-08-27 Інсайт Корпорейшн 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
WO2015187088A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
UY36196A (es) 2014-07-25 2016-02-29 Bayer Animal Health Gmbh Compuestos para usar en el tratamiento antihelmíntico
JP2015051963A (ja) 2014-07-30 2015-03-19 住友化学株式会社 有害生物防除組成物および有害生物の防除方法
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
WO2016028391A2 (en) 2014-08-18 2016-02-25 Hudson Biopharma Inc. Spiropyrrolidines as mdm2 inhibitors
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
WO2016097031A1 (en) 2014-12-18 2016-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Gsk3b and uses thereof in the diagnostic and treatment of hypopigmentation disorders
DK3234597T3 (da) 2014-12-18 2022-02-07 Inst Nat Sante Rech Med Proteiner af WNT-signalvejen og anvendelser deraf i diagnostik og behandling af hypopigmenteringssygdomme
EP3265453B1 (en) 2015-03-05 2022-06-29 Boehringer Ingelheim International GmbH New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
US10292986B2 (en) 2015-05-01 2019-05-21 The Board Of Regents Of The University Of Texas System Methods for treating epithelian mesenchymal transition related diseases
PT3292105T (pt) 2015-05-04 2019-12-13 Astrazeneca Ab Derivados de pirazolo úteis como inibidores da proteína ativadora de 5-lipoxigenase (flap)
JP2017137283A (ja) 2015-05-15 2017-08-10 日産化学工業株式会社 ５−アルキニルピリジン化合物及びその製造方法
KR20170030311A (ko) 2015-09-09 2017-03-17 주식회사 무한 박막형 태양전지 및 그 제조 방법
EP3383874A1 (de) 2015-12-03 2018-10-10 Bayer CropScience Aktiengesellschaft Mesolonische halogenierte 3-(acetyl)-1-[(1,3-thiazol-5-yl)methyl]-1h-imidazo[1,2-a]pyridin-4-ium-2-olat derivate und verwandte verbindungen als insektizide
AR107360A1 (es) 2016-01-13 2018-04-25 Gruenenthal Gmbh Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
CN107151207B (zh) 2016-03-03 2020-09-11 中国科学院上海药物研究所 一种(+)-丹参素及其类似物的制备方法
EP3442972B1 (en) 2016-04-15 2020-03-04 AbbVie Inc. Bromodomain inhibitors
CN106187854A (zh) 2016-07-15 2016-12-07 常熟理工学院 5‑取代‑4‑溴‑1h‑吡咯‑2‑甲酸酯类化合物及其制备方法
GB201614934D0 (en) 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614940D0 (en) 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
WO2018087160A1 (en) 2016-11-09 2018-05-17 I-Tech Ab Substituted heterocyclic compounds for use in controlling parasitic crustaceans on fish
CN108069958A (zh) 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
CN110167939B (zh) 2017-01-11 2021-12-31 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
JOP20190192A1 (ar) 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين
WO2018162312A1 (en) 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
EP3595777A4 (en) 2017-03-14 2021-01-20 Dana-Farber Cancer Institute, Inc. LOW MOLECULAR SENSITIVITY OF BAX ACTIVATION FOR INDUCING CELL DEATH
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
EP3612522A4 (en) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
CN109384784B (zh) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 磺酰胺类衍生物、其制备方法及其在医药上的用途
CN109384785B (zh) * 2017-08-10 2021-09-28 浙江海正药业股份有限公司 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途
GB201713784D0 (en) 2017-08-29 2017-10-11 E-Therapeutics Plc Modulators of hedgehog (Hh) Signalling pathway
WO2019089442A1 (en) 2017-10-30 2019-05-09 Bristol-Myers Squibb Company Aminoimidazopyridines as kinase inhibitors
JP6924677B2 (ja) 2017-11-22 2021-08-25 日本化薬株式会社 ピラジン化合物
BR112020012527A2 (pt) 2017-12-20 2020-11-24 Betta Pharmaceuticals Co., Ltd composto que funciona como inibidor de proteína com bromodomínio, e composição
CN110041253B (zh) 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
CN112236172A (zh) 2018-01-30 2021-01-15 福宏治疗公司 用于治疗病症的方法和化合物
JP2021512960A (ja) 2018-02-06 2021-05-20 シャンハイ ハイファ ファーマシューティカル カンパニー，リミティッド Ｂｅｔ阻害活性を有する化合物並びにその製造方法及び使用
FI3770162T3 (fi) 2018-03-20 2023-06-02 Sumitomo Pharma Co Ltd Dihydrokromeenijohdannainen
WO2019184919A1 (zh) 2018-03-27 2019-10-03 成都海创药业有限公司 一种含有金刚烷的化合物及其在治疗癌症中的用途
AU2019276359B2 (en) 2018-05-30 2024-10-03 Qurient Co., Ltd. Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R
CN110577526B (zh) 2018-06-07 2023-10-27 上海翰森生物医药科技有限公司 溴域结构蛋白抑制剂的盐及其制备方法和应用
CN108690020A (zh) 2018-07-04 2018-10-23 清华大学 一种靶向降解bet蛋白的化合物及其应用
WO2020007322A1 (zh) 2018-07-04 2020-01-09 清华大学 一种靶向降解bet蛋白的化合物及其应用
IT201800007183A1 (it) 2018-07-13 2020-01-13 Composti e composizioni per il trattamento della fibrosi cistica
AU2019302610B2 (en) 2018-07-13 2023-11-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Fused tri-cyclic compound as PDE3/PDE4 dual inhibitor
CN115716827A (zh) 2018-07-25 2023-02-28 正大天晴药业集团股份有限公司 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
WO2020022412A1 (ja) 2018-07-25 2020-01-30 三井化学アグロ株式会社 ピリドン化合物およびそれを有効成分とする農園芸用殺菌剤
CN110776508B (zh) 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
WO2020033413A2 (en) 2018-08-07 2020-02-13 Tosk, Inc. Modulators of ras gtpase
GB201814167D0 (en) 2018-08-31 2018-10-17 Glaxosmithkline Ip No 2 Ltd Compounds
US12084426B2 (en) 2018-09-13 2024-09-10 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
WO2020063976A1 (zh) 2018-09-29 2020-04-02 如东凌达生物医药科技有限公司 一类稠杂环联芳基苄醇类化合物、制备方法和用途
WO2020072492A1 (en) 2018-10-02 2020-04-09 Baruch S. Blumberg Institute Benzamide derivatives as cgas-sting pathway agonists
WO2020092638A1 (en) 2018-10-30 2020-05-07 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2020207953A1 (en) 2019-01-18 2021-08-26 Hangzhou Bangshun Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
WO2020169698A1 (en) 2019-02-21 2020-08-27 F. Hoffmann-La Roche Ag Sensitization of cancer cells to tnf by bet inhibition
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
KR102894020B1 (ko) 2019-05-03 2025-12-04 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020253711A1 (zh) 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
EP3986874A1 (en) 2019-06-21 2022-04-27 Bayer Aktiengesellschaft Benzylphenyl hydroxyisoxazolines and analogues as new antifungal agents
CN110143961B (zh) 2019-06-27 2022-03-29 江苏省中医药研究院 一种基于vhl配体诱导bet降解的吡咯并吡啶酮类双功能分子化合物
CN110204543B (zh) 2019-06-27 2022-03-29 江苏省中医药研究院 一种基于Cereblon配体诱导BET降解的吡咯并吡啶酮类双功能分子化合物
CN114286818B (zh) 2019-07-02 2024-09-20 诺维逊生物股份有限公司 作为bet抑制剂的杂环化合物
WO2021016102A1 (en) 2019-07-19 2021-01-28 Bridgene Biosciences, Inc. Inhibitors of tyrosine kinase
JP7287929B2 (ja) 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬
CN112625036A (zh) 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
GB202001564D0 (en) 2020-02-05 2020-03-18 Kings College Compounds
WO2021178525A1 (en) 2020-03-03 2021-09-10 The University Of Chicago Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors
CN111533721B (zh) 2020-05-15 2022-04-26 浙江大学 苯并吡喃酮或喹啉酮类化合物及其应用
CA3183401A1 (en) 2020-05-19 2021-11-25 Board Of Regents, The University Of Texas System Methods for the treatment of pancreatitis and prevention of pancreatic cancer
WO2022046682A1 (en) 2020-08-26 2022-03-03 Mdi Biological Laboratory Bromodomain and extra terminal domain (bet) inhibitor compositions and methods thereof for use as anti-aging agents
TW202227063A (zh) 2020-10-09 2022-07-16 美商史考皮恩治療有限公司 治療癌症之方法
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
CN113185404B (zh) 2021-04-30 2022-08-05 武汉大学 一种1,2-双轴手性联芳基化合物及其制备方法和应用
MX2024000238A (es) 2021-06-29 2024-01-30 Tay Therapeutics Ltd Derivados de pirrolopiridona utiles en el tratamiento del cancer.
US20250339409A1 (en) 2021-11-03 2025-11-06 Vyne Therapeutics Inc. Uses of pan bet inhibitors
WO2024018423A1 (en) 2022-07-21 2024-01-25 Tay Therapeutics Limited Pyrroles and imidazoles as bet protein inhibitors
AU2023411012A1 (en) 2022-12-23 2025-07-03 Tay Therapeutics Limited Selective bet inhibitors and uses thereof
WO2024220589A2 (en) 2023-04-18 2024-10-24 Vyne Therapeutics Inc. Uses of pan bet inhibitors cross-reference to related applications

Also Published As

Publication number Publication date
US20220204500A1 (en) 2022-06-30
CN113924298A (zh) 2022-01-11
WO2020216779A1 (en) 2020-10-29
ZA202109179B (en) 2023-10-25
JP2025080251A (ja) 2025-05-23
EP3958976B1 (en) 2025-06-11
EP3958976A1 (en) 2022-03-02
IL287470A (en) 2021-12-01
JP2022530405A (ja) 2022-06-29
PT3958976T (pt) 2025-08-27
FI3958976T3 (fi) 2025-09-08
US12384777B2 (en) 2025-08-12
GB2597228A (en) 2022-01-19
EP4616856A2 (en) 2025-09-17
EP4616856A3 (en) 2025-10-29
MX2021013014A (es) 2022-01-18
DK3958976T3 (da) 2025-09-08
GB2597228B (en) 2022-11-30
EA202192905A1 (ru) 2022-02-17
CA3148317A1 (en) 2020-10-29
JP7671503B2 (ja) 2025-05-02
EP3958976B8 (en) 2025-08-13
EP3958976B9 (en) 2025-09-03
GB201905721D0 (en) 2019-06-05
AU2020263112A1 (en) 2021-12-16
GB202116739D0 (en) 2022-01-05
IL287470B1 (en) 2024-02-01
BR112021021284A2 (pt) 2022-01-18
CN120398879A (zh) 2025-08-01
KR20220012250A (ko) 2022-02-03
IL287470B2 (en) 2024-06-01
ES3040060T3 (en) 2025-10-28

Similar Documents

Publication Publication Date Title
PL3958976T3 (pl) Związki zawierające n-metylo-2-pirydon i sole dopuszczalne farmaceutycznie
IL288816A (en) Aminobenzazepine compounds, immunoconjugates and uses thereof
GB201903767D0 (en) Multimers, tetramers & octamers
PT3957436T (pt) Cabeçote de usinagem com correção ativa, método de funcionamento do cabeçote e utilização do mesmo
IL292263A (en) Alternative compounds 4-aminoisoindoline-1,3 dione and second active substances for combined use
LT3348547T (lt) Benzimidazolo dariniai, kaip nav 1.7 (nuo įtampos priklausančio natrio kanalo ix tipo alfa subvieneto (scn9a)) inhibitoriai, skirti skausmui, dizurijai ir išsėtinei sklerozei gydyti
PT3643717T (pt) Compostos de pirrolo triazina substituídos na posição 7 ou sais farmaceuticamente aceitáveis dos mesmos e método de preparação dos mesmos e utilizações dos mesmos
HUP1800441A1 (hu) Aktív szék, elsõsorban irodai használatra
PL3760633T3 (pl) Oksazynochinazolina i związek typu oksazynochinazoliny, sposób ich wytwarzania i ich zastosowania
GB2610935B (en) Flavour system
GB201910299D0 (en) Medical uses, methods and uses
GB201907832D0 (en) Medical uses, methods and uses
GB202011508D0 (en) .
WO2019203748A3 (en) The composition comprising raloxifene with at least one antipsychotic agent
HK1254687A1 (zh) 用於癌症的联合疗法
Schnepf Framing Minorites
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
GB202009556D0 (en) .
WO2019203746A3 (en) The pharmaceutical combination comprising raloxifene and aripiprazole
GB202114277D0 (en) Laptable.
GB202104377D0 (en) Mamama400...
GB202104380D0 (en) mamama400..
GB202104366D0 (en) Mamama400....
IL268717A (en) Luxury maps - Mebasa breaks down with insulation
HK40067178A (en) Aminobenzazepine compounds, immunoconjugates, and uses thereof